BEAM is up 12.53% today. Volume is 2.78M vs a 30-day average of 1.79M (1.56x).
Beam Therapeutics Inc. is scheduled to report earnings Mon, Nov 9, 2026. Analysts expect EPS of $-1.18 on revenue of about $8.93M. Stocks often move sharply on earnings day.
BEAM-301 is a one-time liver-targeted treatment designed to correct a common genetic error that causes glycogen storage disease type Ia, or GSDIa.
Beam Therapeutics (NASDAQ:BEAM) reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A …
In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety…
The data will be presented during a poster session at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany. BEAM-301 is an investi…